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Abstract
The recent outbreak of the COVID-19 pandemic has caused
a re-evaluation of the effectiveness of convalescent plasma
therapy (CPT). This review was carried out to assess the usefulness of CPT in critically ill COVID-19 patients based on the
published data to date. To the best of our knowledge, this
is the second review of the usefulness of CPT in COVID-19
patients. PubMed, Google Scholar, MEDLINE, and Embase
databases were searched for relevant reports up to June 21,
2020. Records of published data were analyzed according to
eligibility criteria. Five different studies on CPT for critically
ill COVID-19 patients were included in this review. The sig-

nificant findings from these records are: (a) CPT may help
to reduce mortality in the critically ill patients (b) administration of CPT increased antibody titers and reduced the level
of severe acute respiratory syndrome coronavirus-2 (SARSCoV-2) RNA to below the detection limit (c) transfusion of convalescent plasma (CP) caused clinical symptoms to subside.
Based on the currently available data, CPT in COVID-19 patients seems effective and safe and reduces mortality. There
is an urgent need to perform well-designed, multicenter clinical trials to establish the efficacy of CPT in COVID-19 patients.

Introduction

the main cause of mortality.[5] Until now, no specific
antiviral drugs and vaccine have been found to cure
and prevent the infection. Therefore, it is necessary
to discuss scientifically and ethically all the therapeutic options for the lethal COVID-19 infections.[5] Several treatment options such as favipiravir and remdesivir are under investigation, but their antiviral efficacy
is not yet known.[6]

Coronavirus is one of the major pathogens that predominantly affect respiratory system of human beings. Epidemics of the coronaviruses in the past
include SARS-CoV and the Middle East respiratory
syndrome coronavirus (MERS-CoV) have been identified as agents that are threat to the public health.[1]
Many patients having pneumonia like symptoms of
unknown cause were admitted to hospitals in late December 2019. Epidemiological studies linked these patients to a wet animals and seafood wholesale markets
in the Wuhan city of Hubei (Province) of China, and
spread to other parts of China and now it has become a
global threat.[1, 2] As of 24 June 2020, World Health Organization (WHO) reported 9,129,146 confirmed cases
of COVID-19 and 473,797 deaths worldwide.[3]
The potential outbreak of the coronavirus was predicted in the early reports, which had given estimate of
reproduction number for the SARS-CoV-2 significantly
greater than one (2.24–3.58).[4] Most of the COVID19 patients are either asymptomatic or presents with
mild symptoms, and in some patients it progresses
to severe acute respiratory syndrome (SARS) which is
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In the past, the passive immunotherapy (PIT) has been
used as a possible treatment option when no proven
drugs or specific vaccine was available for the emerging infections.[7, 8] It has been used as an empirical therapy during the Ebola virus outbreak in 2014,
and a treatment protocol of MERS-CoV with convalescent therapy was developed in 2015.[9] This therapeutic approach with convalescent plasma (CP) for other
viral infections such as H1N1 influenza, H5N1 avian
influenza and SARS-CoV has also suggested that the
transfusion of CP had good results.[10, 11] As a result,
transfusion of CP has gotten attention particularly in
large-scale epidemics.[12] The Food and Drug Administration has recently suggested that the transfusion of
the CP may be effective for the treatment of the COVID19 patients amidst this public health emergency.[13]

1

ULJRI
We conducted this review to assess the available reports for the effectiveness of the CP in COVID-19 patients. It may provide scientific evidence of the potential treatment options to scientists and clinicians for the
better management of the severe ill COVID-19 patients.

What is Convalescent Plasma (CP)?
Most people who recover from COVID-19 develop antibodies (glycoproteins that are produced by the immune system in reaction to infections) to SARS-CoV2. Antibodies are found in plasma. The plasma is collected from the COVID-19 recovered patients through a
process called apheresis. This plasma is called CP. [14]

Who Can Become a CP Donor?
Currently, people recovered from COVID-19 who had
a confirmed positive test result can donate plasma after
they have been symptom free for at least 14 days. People who recover from suspected COVID-19 but never
had a confirmed positive test result can also become
donors if tests show they have SARS-CoV-2 antibodies.
All donors must meet other blood donation criteria.[14]

Dosage of the CP
Different doses of the CP have been for the treatment
of severe ill COVID-19 patients as evident from different studies. A study from China has reported a single dose of CP (200mL) with the neutralizing antibody
titers above 1:640. Another study by reported a maximum dose of CP (2,400mL) for 73 year old male patient.[15] The doses of CP varies in different reports,
the optimal dose of the convalescent is yet to be determined. The CP was administered to all the survivors
between days 6 to 50 days after admission to the hospitals or symptoms onset.

Potential Benefits of CP
CP has been used to treat other infections and may be
beneficial for COVID-19 as well. The researchers hope
that the administration of CP to severe COVID-19 patients may enhance the immune system capability to
fight the virus. Studies are underway to evaluate use of
CP as treatment for patients with severe COVID-19 and
to prevent infection (prophylaxis) in certain high-risk
patients exposed to COVID-19. CP might provide immunity by giving patients neutralizing antibodies for
SARS-CoV-2. Although there is a lot that is unknown,
CP may work best for patients earlier in the disease
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course. Currently, CP is being given to small numbers
of hospitalized patients with severe or life-threatening
COVID-19 illness. Several case reports suggest treatment is helpful, but larger studies are still needed.[14]

Potential Risks of CP
Plasma transfusions are safe and well tolerated by most
patients. Side effects of CP are similar to those of regular plasma transfusions. The most common side effect
is a mild allergic reaction. Rare but serious side effects
include problems with the heart or lungs, or infection.
As with all blood products, CP is thoroughly tested before use. All donated blood is screened for blood type
compatibility as well as infections like hepatitis B and
C, HIV, and many other less common infections. SARSCoV-2 is not spread by blood, and there is no risk of
transmission from recovered donors.[14]

Conclusion
COVID-19 has posed the greatest threat to the globe
and there is urgent need to control it. Currently, no reliable drugs or vaccines are available for curing and preventing COVID-19. Data of the 27 critically ill COVID19 patients in five different studies suggests that in addition to the antimicrobial/antiviral drugs, the CPT can
be an effective therapeutic option (Table 1). It is evident
from data that CPT is safe, improves symptoms and reduces mortality. We recognize that definitive conclusions cannot be obtained on the optimal dose and administration time of CPT to critically ill COVID-19 patients; large clinical trials studies are needed to urgently
tackle the COVID-19 pandemic.
In summary, administration of CP can provide an immediate therapeutic option while assessing the efficacy
of the existing drug and developing new therapies and
specific vaccine. There is urgent need of the following:
1. Identification of donor’s criteria and the eligible
donors.
2. Installing and maintaining blood testing and processing facilities in healthcare settings.
3. Developing serologic assays for screening.
4. Identification of the optimal dose of CP from apheresis collection for critically ill COVID-19 patients. As
data of the natural history of the SARS-CoV-2 is
scarce, the Pandemic Response and Recovery Team
(PRT) should be considered to add a layer of safety
for protection of the recipients of CP.
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Table 1. Five different studies on convalescent plasma therapy for critically ill COVID-19 patients included in this review. All studies were case
series.

Reference

No. of
patients

Timing of
administration

Volume
transfused

Antibody
titer

Patient outcomes

16

5

10–22 days

200 mL
(×2)

>1:1,000

Body temperature was normalized in 4/5 patients
within 3 days of CP administration.
PaO2/FiO2 increased and SOFA score decreased
within 12 days.
ARDS resolved in 4 patients at 12 days.

17

10

16.5 days
(median)

200 mL
(×1)

>1:640

15

4

15.5 days (mean)

200–2,400
mL (1–8
infusions)

—

All 4 patients recovered.

18

2

6–10 days (range)

250 mL
(×2)

—

Removed from mechanical ventilators; tracheostomy
done; extubated and then discharged on the 24th
day.

19

6

33–50 days after
symptoms

500 mL
(×2)

—

Symptoms improved; GGOs resolved by 37th–54th
day; cured and ready to discharge.

Improved oxygenation; reduced viral loads and inflammation.

Abbreviations: CP, convalescent plasma; GGOs, ground glass opacities; SOFA, sequential organ failure assessment.
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